MX2012014849A - Acetato succinato de hidroxipropil metil celulosa con substitucion de acetato de y succinato intensificada. - Google Patents

Acetato succinato de hidroxipropil metil celulosa con substitucion de acetato de y succinato intensificada.

Info

Publication number
MX2012014849A
MX2012014849A MX2012014849A MX2012014849A MX2012014849A MX 2012014849 A MX2012014849 A MX 2012014849A MX 2012014849 A MX2012014849 A MX 2012014849A MX 2012014849 A MX2012014849 A MX 2012014849A MX 2012014849 A MX2012014849 A MX 2012014849A
Authority
MX
Mexico
Prior art keywords
succinate
acetate
methyl cellulose
hydroxypropyl methyl
substitution
Prior art date
Application number
MX2012014849A
Other languages
English (en)
Inventor
Warren K Miller
David K Lyon
Dwayne T Friesen
William B Caldwell
David T Vodak
Daniel E Dobry
Original Assignee
Dow Global Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44627135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012014849(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dow Global Technologies Llc filed Critical Dow Global Technologies Llc
Publication of MX2012014849A publication Critical patent/MX2012014849A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B13/00—Preparation of cellulose ether-esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/32—Cellulose ether-esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Se describen polímeros de acetato succinato de hidroxipropil metil celulosa (HPMCAS) con grados únicos de substitución de grupos hidroxipropoxi, metoxi, acetilo y succinoilo. Cuando se usan para hacer composiciones comprendiendo un agente activo de baja solubilidad y tales polímeros, los polímeros proporcionan concentraciones acuosas incrementadas y/o estabilidad físiça mejorada del agente activo.
MX2012014849A 2010-06-14 2011-06-13 Acetato succinato de hidroxipropil metil celulosa con substitucion de acetato de y succinato intensificada. MX2012014849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35452510P 2010-06-14 2010-06-14
PCT/US2011/040222 WO2011159626A1 (en) 2010-06-14 2011-06-13 Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution

Publications (1)

Publication Number Publication Date
MX2012014849A true MX2012014849A (es) 2013-05-01

Family

ID=44627135

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014849A MX2012014849A (es) 2010-06-14 2011-06-13 Acetato succinato de hidroxipropil metil celulosa con substitucion de acetato de y succinato intensificada.

Country Status (11)

Country Link
US (1) US9040033B2 (es)
EP (1) EP2579896B1 (es)
JP (1) JP5792807B2 (es)
KR (1) KR101807338B1 (es)
CN (1) CN103153343B (es)
BR (1) BR112012031667A2 (es)
CA (1) CA2801712A1 (es)
CO (1) CO6660473A2 (es)
IL (1) IL223607A (es)
MX (1) MX2012014849A (es)
WO (1) WO2011159626A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
MY171941A (en) * 2010-11-24 2019-11-08 Melinta Subsidiary Corp Pharmaceutical compositions
WO2013106433A1 (en) * 2012-01-09 2013-07-18 Virginia Tech Intellectual Properties, Inc. Cellulose derivatives for inhibiting crystallization of poorly water-soluble drugs
JP2015512456A (ja) * 2012-03-27 2015-04-27 ダウ グローバル テクノロジーズ エルエルシー セルロースエーテルのエステルの製造方法
WO2013154607A1 (en) 2012-04-11 2013-10-17 Dow Global Technologies Llc Esterified cellulose ethers having a specific substituent distribution
CN102807625A (zh) * 2012-08-23 2012-12-05 浙江中维药业有限公司 一种醋酸羟丙甲纤维素琥珀酸酯的制备方法
EP2888292B1 (en) * 2012-08-24 2019-04-10 Dow Global Technologies LLC Process for preparing an ester of a cellulose ether in the presence of an alkali metal carboxylate
MX2015002426A (es) * 2012-08-24 2015-06-22 Dow Global Technologies Llc Procedimiento para preparar un eter de celulosa esterificado en presencia de un carboxilato de metal alcalino y un acido carboxilico alifatico.
EP2888293B1 (en) * 2012-08-24 2019-05-08 Dow Global Technologies LLC Novel hydroxyalkyl methyl cellulose acetate succinates
KR102108813B1 (ko) * 2012-08-24 2020-05-12 다우 글로벌 테크놀로지스 엘엘씨 지방족 카복실산의 존재하의 셀룰로스 에테르의 에스테르의 제조 방법
EP2888289B1 (en) 2012-08-24 2019-08-07 Dow Global Technologies LLC Partially cross-linked esterified cellulose ethers
JP6456849B2 (ja) * 2013-03-01 2019-01-23 ハーキュリーズ・インコーポレーテッドＨｅｒｃｕｌｅｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 高められた性能及び改善された加工性を有する医薬組成物
CN105007903B (zh) * 2013-03-07 2020-07-17 陶氏环球技术有限责任公司 具有极高分子量的酯化纤维素醚
BR112015015846A2 (pt) * 2013-03-07 2017-07-11 Dow Global Technologies Llc éter de celulose esterificado, composição, dispersão sólida, forma de dosagem, invólucro de cápsula e processo para produzir um éter de celulose esterificado
KR102110119B1 (ko) * 2013-03-07 2020-05-14 다우 글로벌 테크놀로지스 엘엘씨 저점도 및 고분자량의 신규한 에스테르화된 셀룰로스 에테르
BR112015019807B1 (pt) * 2013-03-07 2020-12-08 Dow Global Technologies Llc acetato succinato de hidroxipropil metilcelulose, composição, dispersão sólida, forma de dosagem e envoltório de cápsula
KR20160006788A (ko) 2013-05-14 2016-01-19 다우 글로벌 테크놀로지스 엘엘씨 디카복실산으로 에스테르화된 셀룰로스 에테르
US10016508B2 (en) 2013-06-03 2018-07-10 Shin-Etsu Chemical Co., Ltd. Composition for hot-melt extrusion and method for producing hot-melt extrusion product using same
WO2015041973A1 (en) * 2013-09-23 2015-03-26 Dow Global Technologies Llc A process for recovering an esterified cellulose ether from a reaction product mixture
KR102286952B1 (ko) * 2013-12-31 2021-08-09 롯데정밀화학 주식회사 입도분포가 조절된 히드록시프로필 메틸셀룰로오스 아세테이트 숙시네이트(hpmcas) 입자의 제조방법 및 hpmcas 분말
BR112016018177A2 (pt) 2014-02-20 2017-08-08 Dow Global Technologies Llc Novos éteres de celulose esterificados de alto peso molecular e homogeneidade
JP7044550B2 (ja) * 2014-08-27 2022-03-30 ニュートリション アンド バイオサイエンシズ ユーエスエー １，リミティド ライアビリティ カンパニー アセトン不溶性含有量の低いエステル化セルロースエーテル
CA2964068A1 (en) * 2014-09-19 2016-03-24 Board Of Regents, The University Of Texas System Methods of preparing extrudates
CN104311674A (zh) * 2014-10-17 2015-01-28 广东东阳光药业有限公司 一种混合酯的制备方法
EP3212674B1 (en) * 2014-10-31 2018-08-22 Dow Global Technologies LLC Process for preparing an ester of a cellulose ether
BR112017008431A2 (pt) * 2014-10-31 2018-01-23 Dow Global Technologies Llc processo para produzir um acetato succinato éter de celulose
KR101839296B1 (ko) * 2014-10-31 2018-03-19 다우 글로벌 테크놀로지스 엘엘씨 셀룰로오스 에테르의 에스테르를 제조하기 위한 효율적인 방법
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
EP3271404B1 (en) * 2015-03-16 2019-01-09 Dow Global Technologies LLC Water-soluble esterified cellulose ethers
EP3270970B1 (en) 2015-03-16 2019-01-09 Dow Global Technologies LLC Gelling esterified cellulose ethers
WO2016148970A1 (en) 2015-03-16 2016-09-22 Dow Global Technologies Llc Aqueous solution of an esterified cellulose ether
US20180030158A1 (en) * 2015-03-16 2018-02-01 Dow Global Technologies Llc Process for preparing an esterified cellulose ether in the presence of an aliphatic carboxylic acid
EP3270971B1 (en) 2015-03-16 2019-01-09 Dow Global Technologies LLC Water-soluble esterified cellulose ethers having a low degree of neutralization
EP3294776B1 (en) 2015-05-15 2020-08-05 Dow Global Technologies LLC Process of preparing a high molecular weight esterified cellulose ether
EP3294777B1 (en) * 2015-05-15 2019-06-26 Dow Global Technologies LLC Process for producing esterified cellulose ethers of very high molecular weight and low viscosity
JP6426877B2 (ja) * 2015-07-28 2018-11-21 ダウ グローバル テクノロジーズ エルエルシー エステル化セルロースエーテルの分散体を生成するためのプロセス
US11142633B2 (en) * 2015-10-02 2021-10-12 Nutrition & Biosciences Usa 1, Llc Aqueous composition comprising dispersed esterified cellulose ether
US20180362737A1 (en) * 2015-12-08 2018-12-20 Dow Global Technologies Llc Compositions comprising cellulose ethers and water-soluble esterified cellulose ethers
US9884922B2 (en) * 2016-03-11 2018-02-06 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate, method for producing the same and composition containing the same
SG11201808949SA (en) 2016-04-15 2018-11-29 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
EP3529281A1 (en) * 2016-10-18 2019-08-28 Dow Global Technologies LLC Efficient process of preparing an esterified cellulose ether
US10888525B2 (en) 2016-11-02 2021-01-12 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate and method for producing the same
JP2020511572A (ja) * 2017-03-17 2020-04-16 ダウ グローバル テクノロジーズ エルエルシー 反応生成物混合物からのエステル化セルロースエーテルの回収方法
AU2018354423A1 (en) * 2017-10-27 2020-05-14 Plexxikon Inc. Formulations of a compound modulating kinases
CA3090125A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CN115651085B (zh) * 2022-11-14 2023-11-17 乳源东阳光药业有限公司 一种醋酸羟丙甲纤维素琥珀酸酯的纯化方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226981A (en) 1977-09-28 1980-10-07 Shin-Etsu Chemical Co., Ltd. Ether-ester derivatives of cellulose and their applications
JP2528706B2 (ja) 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
EP1741424B1 (en) * 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
WO2002038126A2 (en) 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
EP1753402B1 (en) * 2004-05-28 2008-10-01 Pfizer Products Incorporated Pharmaceutical compositions with enhanced performance comprising a hpmca polymer
JPWO2007029660A1 (ja) * 2005-09-06 2009-03-19 アステラス製薬株式会社 腸溶性基剤が表面に吸着した難溶性薬物の微小粒子
WO2007056205A2 (en) 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents

Also Published As

Publication number Publication date
CO6660473A2 (es) 2013-04-30
EP2579896B1 (en) 2016-07-20
IL223607A (en) 2016-04-21
EP2579896A1 (en) 2013-04-17
WO2011159626A1 (en) 2011-12-22
JP5792807B2 (ja) 2015-10-14
CA2801712A1 (en) 2011-12-22
KR101807338B1 (ko) 2018-01-10
BR112012031667A2 (pt) 2016-11-08
US20130102691A1 (en) 2013-04-25
CN103153343A (zh) 2013-06-12
KR20130109102A (ko) 2013-10-07
CN103153343B (zh) 2015-02-11
US9040033B2 (en) 2015-05-26
JP2013532151A (ja) 2013-08-15

Similar Documents

Publication Publication Date Title
MX2012014849A (es) Acetato succinato de hidroxipropil metil celulosa con substitucion de acetato de y succinato intensificada.
WO2005115330A3 (en) Pharmaceutical compositions with enhanced performance
GEP20227342B (en) Formulations of rifaximin and uses thereof
MX2015010398A (es) Composiciones farmaceuticas con rendimiento mejorado y capacidad de procesamiento mejorada.
RS52633B (en) CANCER TREATMENT FORMULATION
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
EP2471926A3 (en) Immunostimulatory oligodeoxynucleotides
BR112013016212A2 (pt) composição aquosa de cuidado oral compreendendo goma xantana, goma de celulose e carbômero.
MX344742B (es) Composicion de formacion de pelicula para capsulas suaves.
EP2556835A4 (en) MIXTURE, DISSOLVANT SOLUTION AND PHARMACEUTICAL AGENT CONTAINING EACH THERMOPHILIC MICROORGANISM
WO2010104310A3 (ko) 크랙 저항성을 갖는 시멘트 모르타르용 혼화제 및 이를 포함하는 시멘트 모르타르
MX2013007230A (es) Sistemas de polimero.
TR201010683A1 (tr) Vildagliptin formülasyonları.
WO2014165513A3 (en) Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof
UA113977C2 (xx) Фармацевтична композиція з покращеною стабільністю
MX2011006567A (es) Formulaciones de fenilefrina con estabilidad mejorada.
RS53714B1 (en) FLURANA KOMPLEKS
BR112015015202B8 (pt) Composição
TR200907227A2 (tr) Çözünürlüğü yüksek stabil mikronize granüller.
MX2016000043A (es) Polisacarido de acido poligulonico sulfatado o sal farmaceutica del mismo, metodo de preparacion del mismo y su uso.
MX2012008317A (es) Uso prebiotico de polisacarido de soja soluble en agua.
TR201102857A2 (tr) Telmisartan ve diüretik kombinasyonunun farmasötik formülasyonları.
BR112012014328A2 (pt) composição de revestimento de película, forma de dosagem fornecida com um revestimento de película, e, uso das composições de revestimento de película

Legal Events

Date Code Title Description
FG Grant or registration